Newsroom

Veeva and ODAIA team up to enhance AI-driven customer insights, helping pharma companies better target and engage healthcare professionals.

Sarah Samuel, a fourth-year PharmD student, gained hands-on AI experience during a rotation at ODAIA, where she collaborated with Peter Zhang on projects to educate engineers about AI's role in healthcare. This exposure deepened her understanding of AI’s potential in pharmacy and its future impact on patient care.

Some of the biggest buzz at Veeva Commercial Summit involved artificial intelligence (AI) applications, an area that Veeva says the company will support with new APIs to make commercial data available to AI apps; the company also announced an AI Partner program to engage with AI developers. The first signup to this program is ODAIA, originally a spinout from the pioneering AI program at the Univ. of Toronto, now focused on "customer science" for commercial pharma applications.

Currently, I am investigating the intersections between pharmacy, science, technology, and business through the lens of entrepreneurship. My research objective is to better understand how to activate the entrepreneurial mindset of pharmacists.

Neo Financial ranks first for the second year in a row in LinkedIn’s sixth annual list of the top 15 startups in Canada as FinTech and AI startups dominate. AltaML, ODAIA, and SantuaryAI are also all notable Canadian AI startups that made this year’s list.

Helen Kontozopoulos spent the last years of her father’s life as his caregiver, and one of her primary memories from this time is just how difficult it was to access information about new, effective drugs.

Toronto-based software startup ODAIA has secured $34 million CAD ($25 million USD) in Series B financing co-led by Threshold Ventures and Monograph Capital, a pair of foreign venture capital investors focused on life sciences and healthtech companies.

After bemoaning the small size of the domestic market, executives at many Canadian tech companies are looking to the U.S. for opportunities‍

ODAIA aims to solve “a really key problem in a very big industry” — how to derive actionable, real-time commercial insights from pharmaceutical sector data.

Toronto-based ODAIA, an AI-powered commercial insights platform for pharmaceutical companies, has raised $13.8 million in Series A funding led by Flint Capital. The platform combines data analysis, process mining and AI to offer predictive analytics to pharmaceutical and life sciences commercial teams. The funding round comes as the company doubled the size of its team over the past year.

Using artificial intelligence (AI), pharmaceutical sales platform ODAIA is attempting to change the way pharma sales reps approach their work. Pharmaceutical Technology sat down with the company to learn more about how its platform works and the successes it has seen so far.